Susquehanna International Group, LLP Regeneron Pharmaceuticals, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$1024.09 - $1201.76 $168 Million - $197 Million	164,000 Added 48.8%	500,100 $526 Million
Q2 2024 Aug 15, 2024	SELL	$883.2 - $1071.19 $42 Million - $51 Million	-47,600 Reduced 12.41%	336,100 $353 Million
Q1 2024 May 07, 2024	SELL	$902.69 - $993.35 $173 Million - $190 Million	-191,300 Reduced 33.27%	383,700 $369 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $4.11 Million - $4.67 Million	-5,300 Reduced 0.91%	575,000 $505 Million
Q3 2023 Nov 14, 2023	SELL	$692.45 - $844.37 $171 Million - $208 Million	-246,900 Reduced 29.85%	580,300 $478 Million
Q2 2023 Aug 11, 2023	SELL	$700.03 - $830.35 $135 Million - $160 Million	-193,100 Reduced 18.93%	827,200 $594 Million
Q1 2023 May 16, 2023	BUY	$680.49 - $826.97 $257 Million - $313 Million	377,900 Added 58.83%	1,020,300 $838 Million
Q4 2022 Feb 14, 2023	SELL	$705.89 - $766.39 $30.7 Million - $33.3 Million	-43,500 Reduced 6.34%	642,400 $463 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $139 Million - $175 Million	241,500 Added 54.34%	685,900 $472 Million

1,535

83.8M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.6B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.